The DOI matches its Crossref record.
A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness
Open accessAbstract
Background: The free prostate-specific antigen (PSA) isoform, [−2]proPSA, has been shown to be associated with prostate cancer. The study objective was to characterize the clinical utility of serum [−2]proPSA for prostate cancer detection and assess its association with aggressive disease. Methods: From among 669 subjects in a prospective prostate cancer detection study at four National Cancer Institute Early Detection Research Network clinical validation centers, 566 were eligible. Serum PSA, free PSA, and [−2]proPSA were measured (Beckman Coulter Access 2 Analyzer). Results: Two hundred and forty-five (43%) of the 566 participants had prostate cancer on biopsy. At 70% specificity, the sensitivity of %[−2]proPSA ([−2]proPSA/fPSA) was 54% [95% confidence interval (CI), 48-61%; null hypothesis, 40%]. Including %[−2]proPSA in a multivariate prediction model incorporating PSA and %fPSA improved the performance (P < 0.01). In the 2 to 4 ng/mL PSA range, %[−2]proPSA outperformed %fPSA (receiver operator characteristic-areas under the curve, 0.73 versus 0.61; P = 0.01). At 80% sensitivity, %[−2]proPSA had significantly higher specificity (51.6%; 95% CI, 41.2-61.8%) than PSA (29.9%; 95% CI, 21.0-40.0%) and %fPSA (28.9%; 95% CI, 20.1-39.0%). In the 2 to 10 ng/mL PSA range, a multivariate model had significant improvement (area under the curve, 0.76) over individual PSA forms (P < 0.01 to <0.0001). At 80% sensitivity, the specificity of %[−2]proPSA (44.9%; 95% CI, 38.4-51.5%) was significantly higher than PSA (30.8%; 95% CI, 24.9-37.1%) and relatively higher than %fPSA (34.6%; 95% CI, 28.5-41.4%). %[−2]proPSA increased with increasing Gleason score (P < 0.001) and was higher in aggressive cancers (P = 0.03). Conclusions: In this prospective study, %[−2]proPSA showed potential clinical utility for improving prostate cancer detection and was related to the risk of aggressive disease. Impact: The addition of %[−2]proPSA could affect the early detection of prostate cancer. Cancer Epidemiol Biomarkers Prev; 19(5); 1193–200. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Catalona, W. J., Partin, A. W., Sanda, M. G., Wei, J. T., Klee, G. G., Bangma, C. H., Slawin, K. M., Marks, L. S., Loeb, S., Broyles, D. L., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.12.032 · Cited by 502
Self-citationAltered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
PSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8505 · Cited by 274
Self-citationAnkerst, D. P., Hoefler, J., Bock, S., Goodman, P. J., Vickers, A., Hernandez, J., Sokoll, L. J., Sanda, M. G., Wei, J. T., Leach, R. J., et al. (2014) · Urology · doi:10.1016/j.urology.2014.02.035 · Cited by 236
Self-citation
Metadata
- Authors
- Sokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J., Mizrahi, I. A., Broyles, D. L., Partin, A. W., Srivastava, S., Thompson, I. M., Wei, J. T., Zhang, Z., & Chan, D. W.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2010-05-01
- Volume
- 19
- Issue
- 5
- Pages
- 1193-1200
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2098546186
- Cited by
- 202
- References
- 0
- FWCI
- 18.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. https://app.cochat.ai/papers/10.1158/1055-9965.epi-10-0007
- The paper
- Sokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J., Mizrahi, I. A., Broyles, D. L., Partin, A. W., Srivastava, S., Thompson, I. M., Wei, J. T., Zhang, Z., & Chan, D. W. (2010). A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-10-0007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.